Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE...
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OK-101 is the first drug candidate to...
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease LONDON and NEW YORK, Aug. 27, 2024 (GLOBE...
OKYO Pharma CEO Interview to Air on Bloomberg TV LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease Encouraging 68% improvement in responder rate...
OKYO Pharma Announces Participation in May 2024 Investor Conferences LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관